No Data
Johnson & Johnson Gets FDA Fast-Track Designation for Posdinemab in Alzheimer's
Express News | Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
Bernstein Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Raises Target Price to $177
Johnson & Johnson (JNJ) Gets a Hold From Bernstein
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $175
Johnson & Johnson (NYSE:JNJ) Jumps to Year's High on Lung Cancer Drug Success
loading...